WO1988008854A1
(en)
|
1987-05-06 |
1988-11-17 |
Egbert Oosterwijk |
Monoclonal antibodies to renal cell carcinoma
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
EP0415929A1
(en)
|
1988-01-15 |
1991-03-13 |
Centocor, Inc. |
Heteroligating antibodies and therapeutic uses thereof
|
AU8727291A
(en)
|
1990-10-29 |
1992-06-11 |
Cetus Oncology Corporation |
Bispecific antibodies, method of production, and uses thereof
|
LU91067I2
(en)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab and its variants and immunochemical derivatives including immotoxins
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5660827A
(en)
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
US6036955A
(en)
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
AU3737893A
(en)
|
1992-03-05 |
1993-10-05 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
EP0871673B1
(en)
|
1995-05-03 |
2006-04-05 |
Bioenhancementsments Ltd. |
Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
|
DE19531346A1
(en)
|
1995-08-25 |
1997-02-27 |
Gsf Forschungszentrum Umwelt |
Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
TR200003087T2
(en)
|
1998-04-21 |
2001-02-21 |
Micromet Ag |
New CD19 X CD3 Specific polypeptides and their use
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
JP4467188B2
(en)
|
1998-10-21 |
2010-05-26 |
アルター・バイオサイエンス・コーポレーション |
Multispecific binding molecules and their use
|
CA2406993A1
(en)
|
2000-03-24 |
2001-09-27 |
Micromet Ag |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
DE10156482A1
(en)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispecific antibody molecule
|
UA87979C2
(en)
|
2002-08-19 |
2009-09-10 |
Астразенека Аб |
Human monoclonal antibody that neutralizes monocyte chemo-attractant protein-1 (mcp-1)
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
DE10261223A1
(en)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Increasing the immune response through substances that influence the function of natural killer cells
|
EP1590372A2
(en)
|
2003-02-06 |
2005-11-02 |
Micromet AG |
Trimeric polypeptide construct to induce an enduring t cell response
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
ATE455127T1
(en)
|
2003-05-31 |
2010-01-15 |
Micromet Ag |
HUMAN ANTI-HUMAN CD3 BINDING MOLECULES
|
EP1629012B1
(en)
|
2003-05-31 |
2018-11-28 |
Amgen Research (Munich) GmbH |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
EP2292264A3
(en)
|
2003-07-24 |
2012-12-19 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
|
HN2004000285A
(en)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTIBODIES DIRECTED TO c-MET
|
BRPI0415457A
(en)
|
2003-10-16 |
2006-12-05 |
Micromet Ag |
cytotoxically active cd3 specific binding construct, its production process, composition comprising the same, nucleic acid sequence, vector, host, its uses in the preparation of a pharmaceutical composition and kit comprising the same
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
MXPA06009253A
(en)
|
2004-02-16 |
2007-04-18 |
Micromet Ag |
Less immunogenic binding molecules.
|
EA010374B1
(en)
|
2004-07-16 |
2008-08-29 |
Микромет Аг |
Expression-enhanced polypeptides
|
BRPI0513681A
(en)
*
|
2004-07-22 |
2008-05-13 |
Genentech Inc |
compositions comprising her2 antibody, method, pharmaceutical formulations, polypeptide, antibody and cancer treatment method
|
EP1809669A2
(en)
|
2004-10-01 |
2007-07-25 |
Avidex Ltd |
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
|
DOP2006000029A
(en)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
|
JP5838021B2
(en)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP2006316040A
(en)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(r) adjuvant treatment
|
WO2007002905A1
(en)
|
2005-06-29 |
2007-01-04 |
University Of Miami |
Antibody-immune cell ligand fusion protein for cancer therapy
|
EP1928495A2
(en)
|
2005-08-19 |
2008-06-11 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
PE20071101A1
(en)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
POLYPEPTIDES AND ANTIBODIES
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
AU2006301163B2
(en)
|
2005-10-14 |
2012-02-23 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
WO2007048849A1
(en)
|
2005-10-28 |
2007-05-03 |
Novo Nordisk A/S |
Fusion proteins that bind effector lymphocytes and target cells
|
EP1945674A2
(en)
|
2005-11-03 |
2008-07-23 |
Genentech, Inc. |
Therapeutic anti-her2 antibody fusion polypeptides
|
EP1949107A1
(en)
|
2005-11-03 |
2008-07-30 |
Fred Hutchinson Cancer Research Center |
Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
|
RS53905B1
(en)
|
2005-12-16 |
2015-08-31 |
Amgen Research (Munich) Gmbh |
Means and methods for the treatment of tumorous diseases
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
MX2009002174A
(en)
|
2006-09-07 |
2009-03-12 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof.
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
KR20100021601A
(en)
|
2007-05-14 |
2010-02-25 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
CA2694396A1
(en)
|
2007-07-25 |
2009-01-29 |
Astrazeneca Ab |
Targeted binding agents directed to kdr and uses thereof - 035
|
MX2010001684A
(en)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Compositions and methods for modifying properties of biologically active polypeptides.
|
JOP20080381B1
(en)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
|
EP2193146B1
(en)
|
2007-09-14 |
2016-05-25 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP2222706B2
(en)
|
2007-12-14 |
2016-08-10 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
CA2712697A1
(en)
|
2008-01-22 |
2009-07-30 |
Biogen Idec Ma Inc. |
Ron antibodies and uses thereof
|
MX2010013236A
(en)
*
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof.
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
US9273136B2
(en)
*
|
2008-08-04 |
2016-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human anti-human NKG2D monoclonal antibodies
|
JP2012503490A
(en)
|
2008-09-26 |
2012-02-09 |
ワイス・エルエルシー |
Single chain antibody library design
|
US9403904B2
(en)
|
2008-11-07 |
2016-08-02 |
Fabrus, Inc. |
Anti-DLL4 antibodies and uses thereof
|
ES2550384T3
(en)
|
2008-12-18 |
2015-11-06 |
Dana-Farber Cancer Institute, Inc. |
NKG2D-Fc for immunotherapy
|
CN106432503B
(en)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
Covalent diabodies and uses thereof
|
AU2010233994A1
(en)
|
2009-04-07 |
2011-09-22 |
Roche Glycart Ag |
Bispecific anti-ErbB-3/anti-c-Met antibodies
|
US20120058082A1
(en)
|
2009-05-13 |
2012-03-08 |
Genzyme Corporation |
Methods and compositions for treatment
|
WO2010144295A1
(en)
|
2009-06-09 |
2010-12-16 |
University Of Miami |
Aptamer-targeted costimulatory ligand aptamer
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR101679602B1
(en)
|
2009-09-11 |
2016-11-25 |
다카라 바이오 가부시키가이샤 |
Process for production of natural killer cells
|
CN102711822A
(en)
|
2009-10-27 |
2012-10-03 |
米克罗麦特股份公司 |
Dosage regimen for administering a CD19xCD3 bispecific antibody
|
US8999398B2
(en)
|
2009-11-06 |
2015-04-07 |
Transtarget Inc. |
Polyclonal bispecific antibody compositions and method of use
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
MX2012007055A
(en)
|
2009-12-18 |
2012-10-15 |
Amgen Inc |
Wise binding agents and epitopes.
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
US20120294857A1
(en)
|
2010-01-11 |
2012-11-22 |
Trustees Of Dartmouth College |
Monomeric Bi-Specific Fusion Protein
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
SG183847A1
(en)
|
2010-03-04 |
2012-10-30 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
TWI653333B
(en)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
Cross-species specific PSMAxCD3 bispecific single chain antibody
|
SG10201800757TA
(en)
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
JP6029581B2
(en)
|
2010-06-19 |
2016-11-24 |
メモリアル スローン−ケタリング キャンサー センター |
Anti-GD2 antibody
|
UY33492A
(en)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
DE102010039018B4
(en)
|
2010-08-06 |
2013-02-28 |
Technische Universität Dresden |
Anti-La antibodies and their use for immuno-targeting
|
US20130177555A1
(en)
|
2010-08-13 |
2013-07-11 |
Medimmune Limited |
Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
|
KR101586128B1
(en)
|
2010-08-24 |
2016-01-15 |
에프. 호프만-라 로슈 아게 |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
EP2614085B1
(en)
|
2010-09-10 |
2016-04-20 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
AR083705A1
(en)
|
2010-11-04 |
2013-03-13 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2012064792A2
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
JP2014511836A
(en)
|
2011-03-25 |
2014-05-19 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
Heterodimeric immunoglobulin
|
CN107936121B
(en)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
Multispecific FAB fusion proteins and methods of use thereof
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CN106432506A
(en)
*
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
Multivalent and monovalent multispecific complexes and their uses
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
EP2723362A1
(en)
|
2011-06-21 |
2014-04-30 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
RU2641256C2
(en)
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Heterodimerizated polypeptide
|
DE102011118022B4
(en)
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antibodies against the prostate-specific stem cell antigen and its use
|
CA2842649C
(en)
|
2011-07-22 |
2020-01-21 |
Affimed Therapeutics Ag |
Multivalent antigen-binding fv molecule
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
JP6322411B2
(en)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
|
RU2732151C2
(en)
|
2011-09-30 |
2020-09-11 |
Чугаи Сейяку Кабусики Кайся |
Library of concentration-dependent binding molecules
|
ES2628075T3
(en)
|
2011-12-19 |
2017-08-01 |
Synimmune Gmbh |
Bispecific antibody molecule
|
WO2013120012A2
(en)
|
2012-02-08 |
2013-08-15 |
Igm Biosciences Inc. |
Cdim binding proteins and uses thereof
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
US9029510B2
(en)
|
2012-03-30 |
2015-05-12 |
Sorrento Therapeutics, Inc. |
Fully human antibodies that bind to VEGFR2 and methods of use thereof
|
JP6393255B2
(en)
|
2012-04-20 |
2018-09-19 |
メルス ナムローゼ フェンノートシャップ |
Methods of producing heterodimeric IgG-like molecules, heterodimeric IgG-like molecules, heterodimeric antibodies, recombinant host cells, pharmaceutical compositions, methods of making host cells, and cultures
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
TWI617578B
(en)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
Target tissue-specific antigen binding molecule
|
WO2013187495A1
(en)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
JP6429771B2
(en)
|
2012-06-21 |
2018-11-28 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen binding protein that binds to c-Met
|
MX354862B
(en)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof.
|
BR112015000798A2
(en)
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
IN2015DN01299A
(en)
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
T-cell redirecting bispecific antibodies for treatment of disease
|
WO2014051433A1
(en)
|
2012-09-27 |
2014-04-03 |
Merus B.V. |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
JP6571527B2
(en)
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
AU2013352812B2
(en)
|
2012-11-27 |
2019-06-20 |
Ajou University Industry-Academic Cooperation Foundation |
CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
KR20210096697A
(en)
*
|
2013-01-10 |
2021-08-05 |
젠맵 비. 브이 |
Human igg1 fc region variants and uses thereof
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
CN111848796A
(en)
|
2013-02-05 |
2020-10-30 |
英格玛布有限责任公司 |
Method for selecting antibodies against BCMA
|
MY192312A
(en)
|
2013-02-26 |
2022-08-17 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
AU2014244286B2
(en)
|
2013-03-14 |
2018-11-08 |
Duke University |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
KR102561553B1
(en)
*
|
2013-03-15 |
2023-07-31 |
젠코어 인코포레이티드 |
Heterodimeric proteins
|
US10167341B2
(en)
|
2013-03-15 |
2019-01-01 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
US10858417B2
(en)
*
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
US10156574B2
(en)
|
2013-04-29 |
2018-12-18 |
Adimab, Llc |
Polyspecificity reagents, methods for their preparation and use
|
AU2014264951A1
(en)
|
2013-05-10 |
2015-11-12 |
Numab Therapeutics AG |
Bispecific constructs and their use in the treatment of various diseases
|
WO2014198748A1
(en)
|
2013-06-11 |
2014-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
|
EP3022229A1
(en)
|
2013-07-15 |
2016-05-25 |
Novo Nordisk A/S |
Antibodies that bind urokinase plasminogen activator
|
TW202100181A
(en)
|
2013-07-16 |
2021-01-01 |
美商建南德克公司 |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
PT3406633T
(en)
|
2013-07-25 |
2022-05-04 |
Cytomx Therapeutics Inc |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
CA2924252C
(en)
|
2013-09-16 |
2022-01-04 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
|
GB2518221A
(en)
|
2013-09-16 |
2015-03-18 |
Sergej Michailovic Kiprijanov |
Tetravalent antigen-binding protein molecule
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
JP6553069B2
(en)
|
2013-11-07 |
2019-07-31 |
メモリアル スローン ケタリング キャンサー センター |
Anti-WT1 / HLA bispecific antibody
|
DE102013019352A1
(en)
|
2013-11-13 |
2015-09-17 |
Elke Pogge Von Strandmann |
Tri-specific recombinant antibody derivatives for the treatment of malignant diseases by activating an NK cell-based immune response
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
MX2016007576A
(en)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates.
|
WO2015095412A1
(en)
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
CN112062853B
(en)
|
2013-12-20 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
Bispecific HER2 antibodies and methods of use
|
KR20230155605A
(en)
|
2013-12-20 |
2023-11-10 |
제넨테크, 인크. |
Dual specific antibodies
|
WO2015095972A1
(en)
|
2013-12-23 |
2015-07-02 |
The Centre For Drug Research And Development |
Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
|
DK3089994T3
(en)
|
2013-12-30 |
2022-07-04 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
BR112016016114A2
(en)
|
2014-01-15 |
2018-05-22 |
Zymeworks Inc |
CONSTRUCTS CONNECTING ANTIGEN CD19 AND CD3 BI-SPECIFIC.
|
KR102088082B1
(en)
|
2014-03-05 |
2020-03-11 |
유씨엘 비즈니스 리미티드 |
Chimeric antigen receptor(car) with antigen binding domains to the t cell receptor beta constant region
|
JP6588461B2
(en)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist
|
DK3126384T3
(en)
|
2014-04-01 |
2021-01-18 |
Adimab Llc |
MULTISPECIFIC ANTIBODY ANALOGS INCLUDING A COMMON LIGHT CHAIN, AND METHODS FOR THEIR PREPARATION AND USE
|
UA117289C2
(en)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Multispecific antibodies
|
KR102380402B1
(en)
|
2014-04-03 |
2022-03-31 |
아이쥐엠 바이오사이언스 인코포레이티드 |
Modified j-chain
|
TW201542594A
(en)
|
2014-04-11 |
2015-11-16 |
Medimmune Llc |
Bispecific HER2 antibodies
|
EP2930188A1
(en)
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
EP2942629A1
(en)
|
2014-05-08 |
2015-11-11 |
Universität Würzburg |
Predictive markers for successful cancer immunotherapy
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
WO2015184203A1
(en)
|
2014-05-29 |
2015-12-03 |
Macrogenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
WO2015197582A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Monomeric multispecific antigen binding proteins
|
EP3161002A1
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
CA2952532A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
US10556964B2
(en)
|
2014-07-21 |
2020-02-11 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
|
RU2747384C2
(en)
|
2014-07-21 |
2021-05-04 |
Новартис Аг |
Cancer treatment with chimeric cd33 antigen receptor
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
JO3663B1
(en)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
Anti-lag3 antibodies and antigen-binding fragments
|
EP3186282A1
(en)
|
2014-08-28 |
2017-07-05 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
EP3215531A1
(en)
|
2014-11-03 |
2017-09-13 |
Merck Patent GmbH |
Methods for generating bispecific shark variable antibody domains and use thereof
|
JP6721590B2
(en)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Multispecific antibody
|
RS63149B1
(en)
|
2014-12-05 |
2022-05-31 |
Xyphos Biosciences Inc |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
CA2970255A1
(en)
|
2014-12-17 |
2016-06-23 |
Intrexon Corporation |
Intercalated single-chain variable fragments
|
MX2017007826A
(en)
|
2014-12-19 |
2018-02-13 |
Biotecnol Ltd |
Fusion protein comprising three binding domains to 5t4 and cd3.
|
IL298086A
(en)
|
2015-01-02 |
2023-01-01 |
Takeda Pharmaceuticals Co |
Bispecific antibodies against plasma kallikrein and factor xii
|
EP3245227A4
(en)
|
2015-01-14 |
2018-07-25 |
Compass Therapeutics LLC |
Multispecific immunomodulatory antigen-binding constructs
|
TW201627322A
(en)
*
|
2015-01-26 |
2016-08-01 |
宏觀基因股份有限公司 |
Anti-DR5 antibodies and molecules comprising DR5-binding domains thereof
|
KR102606190B1
(en)
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Bivalent antibodies directed against NKG2D and tumor associated antigens
|
MA41613A
(en)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
US11673957B2
(en)
|
2015-03-10 |
2023-06-13 |
Eureka Therapeutics, Inc. |
Anti-ROR2 antibodies
|
RU2733496C2
(en)
|
2015-03-16 |
2020-10-02 |
Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
Trispecific binding molecules for treating viral hepatitis b infection and bound states
|
MY186708A
(en)
|
2015-04-03 |
2021-08-11 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
HUE054435T2
(en)
|
2015-04-06 |
2021-09-28 |
Subdomain Llc |
De novo binding domain containing polypeptides and uses thereof
|
WO2016164637A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
JP2018524284A
(en)
|
2015-05-18 |
2018-08-30 |
ユーリカ セラピューティックス, インコーポレイテッド |
Anti-ROR1 antibody
|
EP3095792A1
(en)
|
2015-05-19 |
2016-11-23 |
Klinikum rechts der Isar der Technischen Universität München |
T cell receptor with specificity for myeloperoxidase peptide and uses thereof
|
US20180147257A1
(en)
|
2015-05-22 |
2018-05-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
RS60792B1
(en)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
UY36687A
(en)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
ANTIBODIES AGAINST OX40 AND ITS USES
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201300A1
(en)
|
2015-06-12 |
2016-12-15 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
JP6840682B2
(en)
|
2015-06-23 |
2021-03-10 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
Multispecific antigen binding protein
|
US10113003B2
(en)
|
2015-06-23 |
2018-10-30 |
Innate Pharma |
Multispecific NK engager proteins
|
BR112017028101A2
(en)
|
2015-07-06 |
2018-09-04 |
Ucb Biopharma Sprl |
tau binding antibodies
|
WO2017011342A1
(en)
|
2015-07-10 |
2017-01-19 |
Abbvie Inc. |
Igm-or-ige-modified binding proteins and uses thereof
|
CN108137706A
(en)
|
2015-07-15 |
2018-06-08 |
酵活有限公司 |
The bispecific antigen-binding constructs of drug conjugate
|
CA2992539A1
(en)
|
2015-07-16 |
2017-01-19 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
TW202346349A
(en)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
WO2017048824A1
(en)
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
AU2016343987B2
(en)
|
2015-10-29 |
2023-11-23 |
Alector Llc |
Anti-Siglec-9 antibodies and methods of use thereof
|
US11197919B2
(en)
|
2015-11-04 |
2021-12-14 |
City Of Hope |
Chimeric antigen receptors targeting HER2
|
WO2017083545A1
(en)
|
2015-11-10 |
2017-05-18 |
Fred Hutchinson Cancer Research Center |
Nkg2d decoys
|
US20180327499A1
(en)
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
AU2016383475B2
(en)
|
2015-12-28 |
2024-02-22 |
Innate Pharma |
Variable regions for NKp46 binding proteins
|
WO2017124002A1
(en)
|
2016-01-13 |
2017-07-20 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
UY37127A
(en)
|
2016-02-17 |
2017-08-31 |
Macrogenics Inc |
MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME
|
JP2019510812A
(en)
|
2016-02-26 |
2019-04-18 |
イミュネクサス・ピーティーワイ・リミテッド |
Multispecific molecule
|
EP3433281A1
(en)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
KR102514317B1
(en)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
Novel B7-H3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
AU2017251116A1
(en)
|
2016-04-15 |
2018-12-06 |
Zymeworks Inc. |
Multi-specific antigen-binding constructs targeting immunotherapeutics
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CN105906722B
(en)
|
2016-06-24 |
2020-02-07 |
安徽未名细胞治疗有限公司 |
Her2 specific chimeric antigen receptor and application thereof
|
WO2018045090A1
(en)
|
2016-09-01 |
2018-03-08 |
Immunomab, Inc. |
Bispecific antibodies
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
JOP20190134A1
(en)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
Anti-neuropilin antigen-binding proteins and methods of use thereof
|
WO2018148447A1
(en)
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
CN110944651A
(en)
*
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
Multispecific binding proteins for natural killer cell activation and therapeutic uses thereof for treating cancer
|
EP3579878A4
(en)
|
2017-02-10 |
2020-11-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding psma, nkg2d and cd16
|
CN110461361A
(en)
|
2017-02-10 |
2019-11-15 |
蜻蜓治疗公司 |
In conjunction with the albumen of BCMA, NKG2D and CD16
|
US11884732B2
(en)
|
2017-02-20 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Proteins binding HER2, NKG2D and CD16
|
MA47508A
(en)
|
2017-02-20 |
2021-03-17 |
Dragonfly Therapeutics Inc |
CD33, NKG2D AND CD16 BINDING PROTEINS
|
JP2020508998A
(en)
|
2017-02-20 |
2020-03-26 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Proteins that bind to CD123, NKG2D and CD16
|
JP2020510644A
(en)
|
2017-02-20 |
2020-04-09 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Protein binding to GD2, NKG2D and CD16
|
EP3800203A1
(en)
|
2017-02-27 |
2021-04-07 |
Dragonfly Therapeutics, Inc. |
Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
KR20200010428A
(en)
|
2017-05-23 |
2020-01-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
Proteins That Bind to NKG2D, CD16, and ROR1 or ROR2
|
CA3064714A1
(en)
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
AU2018273250A1
(en)
|
2017-05-23 |
2019-12-12 |
Dragonfly Therapeutics, Inc. |
A protein binding NKG2D, CD16 and a tumor-associated antigen
|
MA49769A
(en)
|
2017-07-31 |
2021-04-21 |
Dragonfly Therapeutics Inc |
PROTEINS BINDING TO NKG2D, CD16 AND FLT3
|
JP2020531438A
(en)
|
2017-08-16 |
2020-11-05 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Proteins that bind to NKG2D, CD16, and EGFR, HLA-E, CCR4, or PD-L1
|
EP3672993A4
(en)
|
2017-08-23 |
2021-10-27 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
RU2021110369A
(en)
|
2017-09-07 |
2021-06-01 |
Драгонфлай Терапьютикс, Инк. |
PROTEINS BINDING NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN
|
AU2018331412A1
(en)
|
2017-09-14 |
2020-03-26 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16, and C-type lectin-like molecule-1 (CLL-1)
|
CN112040971A
(en)
|
2018-02-08 |
2020-12-04 |
蜻蜓疗法股份有限公司 |
Combination cancer therapy involving multispecific binding proteins that activate natural killer cells
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
EA202091976A1
(en)
|
2018-02-20 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
VARIABLE ANTIBODY DOMAINS TARGETING CD33 AND THEIR APPLICATION
|
KR20200132875A
(en)
|
2018-02-20 |
2020-11-25 |
드래곤플라이 쎄라퓨틱스, 인크. |
Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use thereof
|
EP3773676A4
(en)
|
2018-04-03 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
WO2019217332A1
(en)
|
2018-05-07 |
2019-11-14 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
CN112423788A
(en)
|
2018-05-16 |
2021-02-26 |
蜻蜓疗法股份有限公司 |
Proteins that bind NKG2D, CD16 and fibroblast activation proteins
|
EA202091977A1
(en)
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
|
EA202091888A1
(en)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
|
JP2021534096A
(en)
|
2018-08-08 |
2021-12-09 |
ドラゴンフライ セラピューティクス, インコーポレイテッド |
Proteins that bind to NKG2D, CD16 and tumor-related antigens
|
PE20220231A1
(en)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
FLT3L-FC FUSION PROTEINS AND METHODS OF USE
|
AR119393A1
(en)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
ANTIBODIES THAT BIND NKG2D
|
MX2022002524A
(en)
|
2019-08-30 |
2022-06-24 |
Dragonfly Therapeutics Inc |
Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment.
|
WO2021226193A1
(en)
|
2020-05-06 |
2021-11-11 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and clec12a
|